No Data
Express News | JPMorgan downgraded junshi bio's H shares rating to underweight.
junshi bio (01877) published Phase 2 study data of anti-PD-1 monoclonal antibody for nasopharyngeal carcinoma, with a patient objective response rate of 61.9%.
On November 6, junshi bio (01877) announced that the latest data of the Phase 2 study on the combination of toripalimab and gemcitabine as first-line treatment for cisplatin-refractory R/M NPC patients with recurrent/metastatic nasopharyngeal cancer has been published in the international journal Cell Reports Medicine.
Increased revenue without increased profits, junshi bio (01877) faces many hidden concerns behind its growth.
In the third quarter, junshi bio increased revenue without increasing profits, reducing research and development expenses to cut losses. However, shareholders faced market scrutiny for reducing their holdings when a new drug was approved.
junshi bio - U (688180): Bright commercial performance, significant year-on-year and quarter-on-quarter reduction in losses on the profit side.
Junshi Bio released the third quarter report of 2024. In the first three quarters of 2024, the company achieved revenue of 1.271 billion yuan, an increase of 28.87% year-on-year, with a net loss attributable to the parent of -0.927 billion yuan, a decrease of 34.12% year-on-year, net of non-recurring gains and losses.
HK stocks unusual movement: junshi bio (01877) is currently down by over 4%, with a net loss of 0.927 billion yuan in the first three quarters. Shareholders have recently collectively reduced their shareholding by over 1%.
junshi bio (01877) is now down more than 4%, as of the time of publication, down 4.2%, at 13.24 Hong Kong dollars, with a turnover of 11.964 million Hong Kong dollars.
Announcement Highlights | In the first three quarters, PetroChina's net profit exceeded 130 billion yuan; The People's Insurance's net profit increased by 77.2% year-on-year in the first nine months of this year.
PetroChina's net profit in the first three quarters exceeded 130 billion yuan, how is the growth rate? The People's Insurance's profit in the year-on-year period increased by nearly 80%, how large is the scale?
No Data
No Data